Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Opinion CV Team Dispatch

December 2022 News Roundup

L.A. McKeown

December 28, 2022

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

Shelley Wood

December 07, 2022

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2022

Shelley Wood

October 03, 2022

News Conference News TCT 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

Michael O'Riordan

September 17, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

L.A. McKeown

August 27, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

Todd Neale

August 01, 2022

News Daily News

Early LV Recovery After TAVI Points to Better 5-Year Survival

Yael L. Maxwell

August 01, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Conference News ESC Heart Failure 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Conference News THT 2022

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

Caitlin E. Cox

February 02, 2022

Advertisement

December 2022 News Roundup

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

TCTMD’s Top 10 Most Popular Stories for September 2022

Pascal TEER Device as Good as MitraClip in Head-to-Head CLASP IID

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 2022 News Roundup

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

TCTMD’s Top 10 Most Popular Stories for July 2022

Early LV Recovery After TAVI Points to Better 5-Year Survival

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Dapagliflozin Boosts Health Status Across LVEF Range

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Guideline-Directed Therapies Underused in Frail HF Patients

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content